Inactive Provider
This provider's NPI has been deactivated on 04/13/2026. The information on this page is historical and may no longer be current.
Total Payments
$9,858
2024 Payments
$397.50
Companies
60
Transactions
632
Medicare Patients
6,614
Medicare Billing
$1.5M
Payment Breakdown by Category
Food & Beverage$9,461 (96.0%)
Education$396.68 (4.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,461 | 620 | 96.0% |
| Education | $396.68 | 12 | 4.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $781.52 | 55 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $729.83 | 55 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $704.73 | 41 | $0 (2024) |
| Janssen Biotech, Inc. | $653.64 | 39 | $0 (2024) |
| Amgen Inc. | $620.30 | 31 | $0 (2022) |
| PFIZER INC. | $519.68 | 53 | $0 (2024) |
| Celgene Corporation | $488.60 | 24 | $0 (2024) |
| Merck Sharp & Dohme LLC | $442.28 | 34 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $418.05 | 34 | $0 (2023) |
| Eisai Inc. | $359.92 | 21 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $397.50 | 20 | AstraZeneca Pharmaceuticals LP ($100.62) |
| 2023 | $956.19 | 48 | EMD Serono, Inc. ($88.81) |
| 2022 | $1,427 | 79 | EISAI INC. ($134.87) |
| 2021 | $135.80 | 3 | Janssen Biotech, Inc. ($99.95) |
| 2020 | $439.08 | 27 | Janssen Biotech, Inc. ($54.17) |
| 2019 | $2,149 | 126 | Amgen Inc. ($310.85) |
| 2018 | $2,391 | 179 | Janssen Biotech, Inc. ($283.14) |
| 2017 | $1,962 | 150 | Genentech USA, Inc. ($302.44) |
All Payment Transactions
632 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: Oncology | ||||||
| 06/25/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.71 | General |
| Category: Hematology | ||||||
| 06/18/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY | Food and Beverage | In-kind items and services | $14.68 | General |
| Category: Oncology | ||||||
| 06/03/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: Oncology | ||||||
| 05/28/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $16.28 | General |
| 05/15/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $15.53 | General |
| Category: ONCOLOGY | ||||||
| 04/30/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $24.06 | General |
| Category: BioOncology | ||||||
| 04/23/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: Iron Deficiency Anemia | ||||||
| 04/22/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $30.64 | General |
| 04/16/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $13.09 | General |
| Category: Oncology | ||||||
| 04/10/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: Oncology | ||||||
| 04/08/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $33.69 | General |
| Category: Oncology | ||||||
| 03/21/2024 | Eisai Inc. | Lenvima (Drug) | Education | Cash or cash equivalent | $13.35 | General |
| Category: Oncology | ||||||
| 03/19/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $23.22 | General |
| Category: Hematology | ||||||
| 03/07/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: Oncology | ||||||
| 02/13/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug), PLUVICTO | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: Oncology | ||||||
| 01/23/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: ONCOLOGY | ||||||
| 01/17/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: Oncology | ||||||
| 01/09/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $16.32 | General |
| Category: Oncology | ||||||
| 01/02/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $22.97 | General |
| Category: Hematology | ||||||
| 12/21/2023 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $15.49 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2023 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $16.64 | General |
| Category: Oncology | ||||||
| 12/13/2023 | EMD Serono, Inc. | BAVENCIO (Drug) | Food and Beverage | Cash or cash equivalent | $45.10 | General |
| Category: Oncology | ||||||
| 11/17/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $17.48 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2023 | PFIZER INC. | INLYTA (Drug), XTANDI, COMIRNATY | Food and Beverage | In-kind items and services | $15.09 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 31 | 1,074 | 3,477 | $234,561 | $90,413 |
| 2022 | 39 | 1,562 | 9,938 | $760,243 | $346,704 |
| 2021 | 49 | 1,766 | 21,388 | $522,439 | $235,730 |
| 2020 | 61 | 2,212 | 36,091 | $1.6M | $809,473 |
Total Patients
6,614
Total Services
70,894
Medicare Billing
$1.5M
Procedure Codes
182
All Medicare Procedures & Services
182 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 37 | 220 | $77,946 | $28,990 | 37.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 77 | 126 | $23,781 | $11,108 | 46.7% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 32 | 127 | $8,890 | $8,800 | 99.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 66 | 96 | $12,767 | $5,774 | 45.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 27 | 64 | $18,688 | $5,626 | 30.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 124 | 456 | $16,142 | $4,655 | 28.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 135 | 535 | $7,725 | $4,221 | 54.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 142 | 505 | $13,347 | $3,783 | 28.3% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 54 | 193 | $12,078 | $3,463 | 28.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $4,212 | $2,044 | 48.5% |
| 82024 | Adrenocorticotropic hormone (acth) level | Office | 2023 | 13 | 44 | $4,730 | $1,665 | 35.2% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 37 | 69 | $4,968 | $1,599 | 32.2% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 19 | 79 | $4,517 | $1,300 | 28.8% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 20 | 48 | $3,097 | $828.64 | 26.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 16 | 19 | $1,551 | $766.44 | 49.4% |
| 84403 | Testosterone (hormone) level, total | Office | 2023 | 21 | 30 | $2,635 | $758.70 | 28.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 14 | 18 | $2,718 | $703.50 | 25.9% |
| 82533 | Cortisol (hormone) measurement, total | Office | 2023 | 13 | 44 | $2,002 | $702.68 | 35.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 17 | 60 | $2,064 | $639.30 | 31.0% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 12 | 89 | $2,225 | $543.43 | 24.4% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 13 | 20 | $1,416 | $407.80 | 28.8% |
| 83735 | Magnesium level | Office | 2023 | 21 | 68 | $1,549 | $402.53 | 26.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 17 | 36 | $1,368 | $349.82 | 25.6% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 13 | 20 | $927.00 | $267.20 | 28.8% |
| 84466 | Transferrin (iron binding protein) level | Office | 2023 | 11 | 16 | $634.88 | $200.00 | 31.5% |
About Dr. Mark Campbell, MD
Dr. Mark Campbell, MD is a Medical Oncology healthcare provider based in Grand Rapids, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1851392948.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Campbell, MD has received a total of $9,858 in payments from pharmaceutical and medical device companies, with $397.50 received in 2024. These payments were reported across 632 transactions from 60 companies. The most common payment nature is "Food and Beverage" ($9,461).
As a Medicare-enrolled provider, Campbell has provided services to 6,614 Medicare beneficiaries, totaling 70,894 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 182 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Grand Rapids, MI
- Active Since 08/10/2005
- Last Updated 03/13/2020
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1851392948
Products in Payments
- IMBRUVICA (Drug) $435.96
- OPDIVO (Biological) $313.79
- KEYTRUDA (Biological) $310.19
- Lenvima (Drug) $296.13
- KISQALI (Drug) $213.38
- TAGRISSO (Drug) $192.29
- IBRANCE (Drug) $184.42
- XTANDI (Drug) $184.17
- ZEJULA (Drug) $156.65
- CYRAMZA (Drug) $143.97
- ERLEADA (Drug) $135.12
- Kyprolis (Biological) $125.04
- LYNPARZA (Drug) $113.74
- JAKAFI (Drug) $113.11
- Abraxane (Drug) $110.56
- Zydelig (Drug) $110.20
- SOMATULINE DEPOT (Drug) $109.55
- Revlimid (Drug) $109.50
- DARZALEX (Biological) $109.27
- JEVTANA (Drug) $104.76
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Grand Rapids
Dr. Sami Brake, Md, MD
Medical Oncology — Payments: $177,248
Medical Oncology $177,248
Dr. Manish Sharma, M.d, M.D
Medical Oncology — Payments: $33,385
Medical Oncology $33,385
Zeyad Sako, Md, MD
Medical Oncology — Payments: $5,245
Medical Oncology $5,245
Jared Knol, Md, MD
Medical Oncology — Payments: $1,432
Medical Oncology $1,432
Alan Campbell, Md, MD
Medical Oncology — Payments: $988.87
Medical Oncology $988.87
Yahya Ibrahim, Md, MD
Medical Oncology — Payments: $428.32
Medical Oncology $428.32